Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
Holding LQDA?
Track your performance easily
LQDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.71 - $16.99
Previous Close$9.78
Volume1.14M
Average Volume (3M)1.24M
Market Cap
$814.23M
Enterprise Value$681.13M
Total Cash (Recent Filing)$133.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding76,793,694
10 Day Avg. Volume1,074,907
30 Day Avg. Volume1,243,001
Standard Deviation0.21
R-Squared0.00301
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)11.93
Price to Sales (P/S)51.75
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue45.90
Enterprise Value/Gross Profit46.65
Enterprise Value/Ebitda-6.73
Forecast
1Y Price Target
$23.50Price Target Upside137.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Liquidia Technologies News
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe 52-week range for the stock is 5.71 USD to 16.99 USD, indicating significant growth potential.
Legal And Regulatory DevelopmentsThe Supreme Court issued a ruling that limits the authority of government agencies like the FDA, which could impede the FDA in making certain arguments.
Product Approval And Market PotentialHigh odds are seen of LQDA’s DPI treprostinil therapy Yutrepia gaining freedom to operate and emerging as the dominant DPI treprostinil product when it becomes commercially available.
Bears Say
Legal ChallengesUnited Therapeutics effectively delayed the final approval and launch of Yutrepia.
Market ImpactA Yutrepia launch push to mid-2025 would have a ~$1/share impact to the discounted cash flow.
Regulatory IssuesFinal approval for Yutrepia is expected only after the expiry of the reference brand's new dosage form regulatory exclusivity.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $5.71 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Currently, no data Available
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 07, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.342 by -$0.028.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -$0.39.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 83,254,370 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.342. Following the earnings report the stock price went down -3.436%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Among the largest hedge funds holding Liquidia Technologies Inc’s share is Farallon Capital Management, L.L.C.. It holds Liquidia Technologies Inc’s shares valued at 25M.
---
Liquidia Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (137.13% Upside)
$23.50 (137.13% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 42.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.62%
12-Months-Change
Fundamentals
Return on Equity
-181.73%
Trailing 12-Months
Asset Growth
45.86%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q2 2024
0:00 / 0:00
---
LQDA Stock 12 Month Forecast
Average Price Target
$23.50
▲(137.13% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+30.75%
assigned a buy rating last month
Copying Julian Harrison's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +30.75% per trade.
---